Skip to content
DataLookout
Menu

NCT07785024

CEST for Prostate Biopsy

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Sep 2026 to Dec 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 5 words
    • Primary and study completion pushed from Sep 2027 to Dec 2027
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
    • Study description expanded, about 2 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Aiding the detection of prostate cancer
Timeframe: 1 year

Secondary (1)

Aiding risk stratification and the decision whether targeted prostate biopsy is justified

Arms and interventions

Diagnostic Test: Saturation Transfer (ST)-MRIExperimental

Non-contrast magnetic resonance imaging "Saturation Transfer" scans consisting of magnetization transfer (MT) and chemical exchange saturation transfer (CEST)

Procedures: Biopsy-Guided Therapy Selection

Sites

1 site in 1 country

  • Sunnybrook Health Sciences CentreToronto, Ontario, Canada